EDEN
PRAIRIE, Minn., March 30,
2022 /PRNewswire/ -- NeuroOne Medical Technologies
Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused on improving surgical care options and
outcomes for patients suffering from neurological disorders, today
announced that a telephone replay of its investor conference call
discussing recent disclosures, held yesterday, will be available
through April 11, 2022. The webcast
replay will be available for one year.
During the investor call, NeuroOne CEO Dave Rosa was joined by Dr. William Wustenberg, a biocompatibility expert
that has worked with over 1500 companies over the past 25 years to
provide guidance on biocompatibility testing required for a variety
of FDA submissions. Mr. Rosa provided clarification regarding the
disclosure included in the Company's Form 8-K filed March 25, 2022 about its 510(k) clearance request
to the FDA for its Evo® sEEG Electrode for less than 30-day use
while Mr. Rosa and Dr. Wustenberg also answered questions submitted
by the public. The device has already been 510(k) cleared for
temporary (less than 24 hours) use.
Telephone Replay
877-660-6853 / 201-612-7415
End Date: 2022-04-11
Access ID: 13728487
Webcast
Replay
https://services.choruscall.com/mediaframe/webcast.html?webcastid=TiuTgwf3
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information,
visit https://www.n1mtc.com .
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-investor-call-replay-available-through-april-11th-301513676.html
SOURCE NeuroOne Medical Technologies Corporation